861 results on '"Byrne, Barry J."'
Search Results
52. Nicholas Muzyczka, PhD [1947–2023]
53. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy
54. Polysomnography findings in children with spinal muscular atrophy after onasemnogene-abeparvovec
55. Gene Delivery to Skeletal Muscle Results in Sustained Expression and Systemic Delivery of a Therapeutic Protein
56. Safety And Feasibility Of Strength Training In Patients With Duchenne Muscular Dystrophy: 3187 Board #233 May 31 3:30 PM - 5:00 PM
57. BAFF blockade prevents anti-drug antibody formation in a mouse model of Pompe disease
58. Addressing the implementation gap in advanced therapeutics for spinal muscular atrophy in the era of newborn screening programs
59. Secondary hemophagocytic lymphohistiocytosis following Zolgensma therapy: An evolving story on the innate response to systemic gene therapy
60. Combination Therapy to Enable AAV Re-Dosing and Mitigate Transgene Immunity in Liver-Targeted Gene Therapy
61. Chemogenetic activation of hypoglossal motoneurons in a mouse model of Pompe disease
62. Correction to: Reduced Muscle Strength in Barth Syndrome May Be Improved by Resistance Exercise Training: A Pilot Study
63. Muscle as a Metabolic Factory for Gene Therapy
64. Hypoglossal Motoneuron (XII MN) Survival Over the Lifespan in Pompe Disease
65. Additional file 4 of Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging
66. Additional file 2 of Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging
67. Additional file 6 of Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging
68. Additional file 3 of Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging
69. Additional file 5 of Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging
70. Additional file 1 of Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging
71. Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity
72. A degradable, bioactive, gelatinized alginate hydrogel to improve stem cell/growth factor delivery and facilitate healing after myocardial infarction
73. MRI/MRS evaluation of a female carrier of Duchenne muscular dystrophy
74. Endurance training ameliorates complex 3 deficiency in a mouse model of Barth syndrome
75. Comparison of highly pure rAAV9 vector stocks produced in suspension by PEI transfection or HSV infection reveals striking quantitative and qualitative differences
76. Advanced therapeutic strategy for hereditary neuromuscular diseases
77. Endurance Exercise Training in Young Adults with Barth Syndrome: A Pilot Study
78. Sustained Transgene Expression despite T Lymphocyte Responses in a Clinical Trial of rAAV1-AAT Gene Therapy
79. Neural Deficits Contribute to Respiratory Insufficiency in Pompe Disease
80. Adeno-Associated Virus and Other New DNA Virus Vectors
81. Human Gene Therapy for RPE65 Isomerase Deficiency Activates the Retinoid Cycle of Vision but with Slow Rod Kinetics
82. Diaphragm pacing as a rehabilitative tool for patients with pompe disease who are ventilator-dependent: case series
83. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial
84. Scratching the surface of RGD-directed AAV capsid engineering
85. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort
86. Reply: Respiratory motor function in centronuclear myopathy
87. Respiratory motor function in individuals with centronuclear myopathies
88. Cardiac responses in paediatric Pompe disease in the ADVANCE patient cohort
89. Resistance exercise training with protein supplementation improves skeletal muscle strength and improves quality of life in late adolescents and young adults with Barth syndrome: A pilot study
90. Case Studies in Neuroscience: Neuropathology and diaphragm dysfunction in ventilatory failure from late-onset Pompe disease
91. Stimulation of Respiratory Motor Output and Ventilation in a Murine Model of Pompe Disease by Ampakines
92. Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease
93. Peripheral nerve and neuromuscular junction pathology in Pompe disease
94. Mapping of the Late Promoter of Simian Virus 40
95. The Simian Virus 40 Minimal Origin and the 72-Base-Pair Repeat are Required Simultaneously for Efficient Induction of Late Gene Expression with Large Tumor Antigen
96. Substrate metabolism during basal and hyperinsulinemic conditions in adolescents and young-adults with Barth syndrome
97. NaCl and KCl mediate log increase in AAV vector particles and infectious titers in a specific/timely manner with the HSV platform
98. Mavis Agbandje-McKenna’s lifelong commitment to teaching and research
99. Gene Delivery to Intestinal Epithelial Cells In vitro and In vivo with Recombinant Adeno-Associated Virus Types 1, 2 and 5
100. Current Clinical Applications of In Vivo Gene Therapy with AAVs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.